CriticalCentrally acting cough suppressant×Selective irreversible MAO-B inhibitor
Updated · Methodology
Mechanism
Selegiline irreversibly inhibits the enzyme monoamine oxidase (MAO), which takes part in the breakdown of catecholamines and serotonin. At recommended doses it acts selectively on MAO type B (selegiline label, US Food and Drug Administration, FDA). Above the recommended 10 mg a day, selegiline may lose this selectivity. After it is stopped, enzyme activity returns to normal in about 2 weeks (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dextromethorphan has mild serotonergic properties. With MAO inhibitors it has caused serotonin syndrome, and the Spanish SmPC names selegiline among these inhibitors (dextromethorphan SmPC, AEMPS). According to the Spanish dextromethorphan SmPC, the reaction may stem from these properties and from slower breakdown of dextromethorphan in the liver (dextromethorphan SmPC, AEMPS).
Symptoms
With monoamine oxidase (MAO) inhibitors, including selegiline, dextromethorphan has caused serotonin syndrome with tremor, clonus, myoclonus, overactive reflexes and rigidity, sweating, fever, fast heart rate and breathing, dilated pupils, agitation and confusion (dextromethorphan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Nausea, coma, low blood pressure, leg tremor, muscle spasms, very high fever and high blood pressure may also occur and can lead to heart attack and death (dextromethorphan orodispersible tablet SmPC, AEMPS). The combination of MAO inhibitors and dextromethorphan has also caused brief episodes of psychosis or bizarre behaviour (selegiline label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated. The Spanish dextromethorphan summaries of product characteristics (SmPCs) name selegiline among the drugs that must not be taken with dextromethorphan at the same time or within 2 weeks of stopping them (dextromethorphan SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). The US selegiline labels, for both tablets and the patch, also contraindicate dextromethorphan (US Food and Drug Administration, FDA). Do not take dextromethorphan until at least 14 days after stopping selegiline (dextromethorphan SmPCs, AEMPS; over-the-counter dextromethorphan FDA label). Selegiline inhibits the enzyme monoamine oxidase (MAO) irreversibly, and MAO-B activity takes about 2 weeks to recover (selegiline SmPC, AEMPS). Before the first selegiline patch after dextromethorphan, wait 4–5 half-lives of dextromethorphan or its active metabolite, about one week (transdermal selegiline FDA label). In Spain, all dextromethorphan products, including combination cold and flu remedies, are sold without a prescription (AEMPS medicines register). Ask patients who take selegiline to mention every over-the-counter medicine they use, especially cold remedies (selegiline FDA label). Sympathomimetics, such as nasal decongestants, are also contraindicated with selegiline because of the risk of high blood pressure (selegiline SmPC, AEMPS). If serotonin syndrome is suspected, stop dextromethorphan (dextromethorphan SmPCs, AEMPS). Benzodiazepines can be used for seizures, and benzodiazepines with external cooling for hyperthermia from serotonin syndrome (dextromethorphan SmPCs, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Selegilina, Plurimen 5 mg (nº registro 58113) (2026)– AEMPS, CIMA, nº registro 58113 (Plurimen 5 mg comprimidos), revisión 03/2026, secciones 4.3, 4.4, 4.5 y 5.1
- FDA: Zelapar (selegiline hydrochloride) prescribing information (2021)– FDA label, Bausch Health US, LLC, DailyMed setid 380d7717-2a79-42f3-a712-efe5e7696ba0, revised 06/2021, sections 4, 5.1 and 7.1
- FDA: Emsam (selegiline transdermal system) prescribing information (2020)– FDA label, Viatris Specialty LLC, DailyMed setid b891bd9f-fdb8-4862-89c5-ecdd700398a3, revised 05/2020, section 4
- AEMPS: Ficha técnica: Dextrometorfano, Laitos 3 mg/ml jarabe (nº registro 70997), sección 4.5 (2026)– AEMPS, CIMA, nº registro 70997, revisión 08/2026, sección 4.5
- AEMPS: Ficha técnica: Dextrometorfano, Cinfatos Antitusivo Flas 15 mg comprimidos bucodispersables (nº registro 85817), sección 4.5 (2025)– AEMPS, CIMA, nº registro 85817, revisión 12/2025, secciones 4.3 y 4.5
- FDA: Delsym Cough (dextromethorphan) OTC Drug Facts label (2026)– FDA, DailyMed, Reckitt Benckiser, setid a43d59f9-3a6c-4a7c-b98d-b86d6035f716, revised 05/2026, Drug Facts: Warnings
- AEMPS: Ficha técnica: Dextrometorfano, Bisolvon Antitusivo 2 mg/ml jarabe (nº registro 57174), sección 4.3 (2026)– AEMPS, CIMA, nº registro 57174 (Opella Healthcare Spain), revisión 01/2026, secciones 4.3, 4.4, 4.5, 4.9 y 5.1